Literature DB >> 26879611

[The expression and clinical role of KL-6 in serum and BALF of patients with different diffuse interstitial lung diseases].

C Zhu1, Y B Zhao, L F Kong, Z H Li, J Kang.   

Abstract

OBJECTIVE: To detect the levels of KL-6 in the serum and the bronchoalveolar lavage fluid (BALF) of patients with different type of diffuse interstitial lung diseases(DILD), and to analyze its correlation with pulmonary function, pulmonary HRCT scores and other parameters.
METHOD: Seventy-three patients with DILD were enrolled, including 34 patients with idiopathic pulmonary fibrosis (IPF), 10 patients with stage Ⅰ sarcoidosis(SAR Ⅰ), 15 patients with hypersensitivity pneumonia (HP), 14 patients with connective tissue diseases (CTD). Enzyme-linked immune sorbent assay (ELISA) was used to detect the levels of KL-6 in the serum and the BALF of these patients.
RESULTS: In the IPF group, FVC predicted percentage and DLCO predicted percentage were significantly lower than those of the SAR Ⅰ group[(70±14)% vs (82±6)%, (49±13)% vs(81±6)%, P<0.05], but were no different compared to the CTD-ILD group(P>0.05). In the IPF group, the percentage of neutrophils in BALF was higher than that of the SAR Ⅰ group[(9±7)% vs (6±4)%, P<0.05]], and the percentage of lymphocytes and CD4/CD8 ratio in BALF were lower than those of the SAR Ⅰ group[(12±7)% vs (23±13)%, (1.5±0.8) vs(4.0±5.1), P<0.05]. In the IPF group, the level of KL-6 in serum was higher than that of the SAR Ⅰ and the HP group[(858±516)U/ml vs (339±168)U/ml, (553±287)U/ml, P<0.05], but was no different compared to the CTD-ILD group (P>0.05). In the CTD-ILD group, the level of KL-6 in serum was higher than that of the SAR Ⅰ [(687±350) U/ml vs (339±168)U/ml, P<0.05]]. In the IPF group, the level of KL-6 in BALF was (437±252)U/ml, and was higher than that of other 3 groups(P<0.05). In the IPF group, the level of serum KL-6 was negatively correlated with FVC and DLCO(r=-0.46, -0.58, P<0.01), the level of serum KL-6 was positively correlated with pulmonary HRCT reticular pattern and honeycombing scores(r=0.62, 0.41, P<0.05).
CONCLUSIONS: In patients with IPF, the levels of KL-6 in serum and BALF were increased and the level of KL-6 in serum was correlated with FVC, DLCO and pulmonary HRCT reticular pattern and honeycombing scores.KL-6 may be a marker for the diagnosis of IPF.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26879611     DOI: 10.3760/cma.j.issn.1001-0939.2016.02.004

Source DB:  PubMed          Journal:  Zhonghua Jie He He Hu Xi Za Zhi        ISSN: 1001-0939


  5 in total

1.  BAL biomarkers' panel for differential diagnosis of interstitial lung diseases.

Authors:  Miriana d'Alessandro; Alfonso Carleo; Paolo Cameli; Laura Bergantini; Anna Perrone; Lucia Vietri; Nicola Lanzarone; Cecilia Vagaggini; Piersante Sestini; Elena Bargagli
Journal:  Clin Exp Med       Date:  2020-01-22       Impact factor: 3.984

2.  Diagnostic value of KL-6 in idiopathic interstitial pneumonia.

Authors:  Peiyan Zheng; Xiaoqing Liu; Huimin Huang; Zijun Guo; Ge Wu; Haisheng Hu; Chuanxu Cai; Wenting Luo; Nili Wei; Qian Han; Baoqing Sun
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

Review 3.  Bronchoalveolar lavage and lung biopsy in connective tissue diseases, to do or not to do?

Authors:  Sara Tomassetti; Thomas V Colby; Athol U Wells; Venerino Poletti; Ulrich Costabel; Marco Matucci-Cerinic
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-12-08       Impact factor: 5.346

4.  Identification of three hub genes related to the prognosis of idiopathic pulmonary fibrosis using bioinformatics analysis.

Authors:  Enze Wang; Yue Wang; Sijing Zhou; Xingyuan Xia; Rui Han; Guanghe Fei; Daxiong Zeng; Ran Wang
Journal:  Int J Med Sci       Date:  2022-08-15       Impact factor: 3.642

Review 5.  Molecular Biomarkers in Idiopathic Pulmonary Fibrosis: State of the Art and Future Directions.

Authors:  Anna Stainer; Paola Faverio; Sara Busnelli; Martina Catalano; Matteo Della Zoppa; Almerico Marruchella; Alberto Pesci; Fabrizio Luppi
Journal:  Int J Mol Sci       Date:  2021-06-10       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.